Full Press Release Details
MedTech Inc. Announces Third Quarter 2022 Results
WORTH, TX / GLOBENEWSWIRE / November 14, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara,"
the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologies
for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, operational and financial
results for the quarter ended September 30, 2022.
Fleming, Sanara's CEO, stated, "The third quarter of 2022 was another revenue record for Sanara, as well as, for our historical
business before we acquired Scendia Biologics. These strong results were driven by increased recognition of the value that our products
provide to patients, as well as the hard work of our entire team. During the third quarter, we worked to integrate Scendia into the Company
and, subsequent to quarter end, we announced the formation of a new chronic wound care partnership with InfuSystem Holdings, Inc. ("InfuSystem").
We look forward to further integrating Scendia into our business and working with InfuSystem to continue to provide highly efficacious
solutions to patients and providers that improve outcomes and reduce costs of care."
Quarter 2022 and Other Recent Strategic and Operational Highlights (Unaudited)
Quarter 2022 Consolidated Financial Results (Unaudited)
Company will host a conference call on Tuesday, November 15, 2022, at 9:00 a.m. Eastern Time. The toll-free number for this teleconference
is 888-506-0062 (international callers: 973-528-0011) and the access code is 729545. A telephonic replay of the conference call will
be available through Tuesday, November 29, 2022, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay
live webcast of Sanara's conference call will be available under the Investor Relations section of the Company's website,
www.SanaraMedTech.com. A one-year online replay will be available after the conclusion of the live broadcast.
a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops
wound and skincare products for use by physicians and clinicians in hospitals, clinics, and all post-acute care settings and offers wound
care and dermatology virtual consultation services via telemedicine. Sanara's products are primarily sold in the North American
advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX Surgical Activated
Collagen , FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix
as well as a portfolio of advanced biologic products focusing on AMPLIFY Verified Inductive Bone Matrix, ALLOCYTE
Advanced Cellular Bone Matrix, BiFORM Bioactive Moldable Matrix and TEXAGEN Amniotic Membrane
Allograft to the surgical market. In addition, the following products are sold to the wound care market: BIAK S
Antimicrobial Skin and Wound Cleanser, BIAK S Antimicrobial Wound Gel, BIAK S Antimicrobial
Skin and Wound Irrigation Solution and HYCOL Hydrolyzed Collagen. Sanara's pipeline also contains potentially
transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic
tissue debridement, and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical
and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships
with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its
six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal,
hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of
the healthcare industry.
about Forward-Looking Statements
statements in this press release that do not constitute historical facts are "forward-looking statements," within the meaning
of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified
by terms such as "anticipates," "believes," "contemplates," "continue," "could,"
"estimates," "expect," "forecasts," "guidance," "intend," "may,"
"plan," "possible," "potential," "predicts," "preliminary," "projects,"
"seeks," "should," "targets," "will" or "would," or the negatives of these
terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding
the ability to successfully integrate Scendia into Sanara's business; the development of new products, the regulatory approval
process and expansion of the Company's business. These items involve risks, contingencies and uncertainties such as the extent
of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated
with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions,
and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual
operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of
these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities
Nichols, Director of Investor Relations